Publications

• Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

  (Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L.) Am J Hematol. 2021 01;96(1):E5-E8 PMID: 32974944 SCOPUS ID: 2-s2.0-85092920395 09/26/2020

• International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

  (Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B.) Leukemia. 2021 01;35(1):18-30 PMID: 32778736 SCOPUS ID: 2-s2.0-85089253567 08/12/2020

• Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.

  (Dhakal B, Hari PN, Usmani SZ, Hamadani M.) Bone Marrow Transplant. 2021 Jan;56(1):9-19 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020

• Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

  (Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A.) Cancer. 2020 Dec 01;126(23):5077-5087 PMID: 32965680 SCOPUS ID: 2-s2.0-85091306660 09/24/2020

• Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

  (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 12;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020

• Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

  (Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ.) Leuk Lymphoma. 2020 12;61(14):3484-3492 PMID: 32865474 PMCID: PMC7786301 SCOPUS ID: 2-s2.0-85089967898 09/01/2020

• In response to American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

  (Reddy P, Davies S, Majhail N, Sandmaier B, Hari P, Cutler C.) Blood Adv. 2020 Nov 10;4(21):5431-5432 PMID: 33152057 PMCID: PMC7656930 SCOPUS ID: 2-s2.0-85096913166 11/06/2020

• Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.

  (Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P.) Br J Haematol. 2020 Nov;191(3):442-452 PMID: 33094839 SCOPUS ID: 2-s2.0-85088463591 10/24/2020

• Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

  (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020

• Autonomic nervous system control of multiple myeloma.

  (Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S.) Blood Rev. 2020 Aug 11:100741 PMID: 32807576 PMCID: PMC7876165 SCOPUS ID: 2-s2.0-85089534779 08/19/2020

• Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets.

  (Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA.) J Immunother Cancer. 2020 08;8(2) PMID: 32771993 PMCID: PMC7418848 SCOPUS ID: 2-s2.0-85089262124 08/11/2020

• African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

  (Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A.) Cancer. 2020 Jan 01;127(1):82-92 PMID: 32966625 PMCID: PMC7736245 SCOPUS ID: 2-s2.0-85091313309 09/24/2020